Oncothyreon Inc. (ONTY) Secures $12.5M Loan to Support Phase II Trials and Operations through 2012

QualityStocks would like to highlight Oncothyreon (NASDAQ: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

In the company’s news yesterday,

Oncothyreon announced it has entered into an aggregate $12.5 million secured loan facility from GE Capital, Healthcare Financial Services.

The initial term loan was for $5.0 million, which was funded February 8, 2011. Oncothyreon has the option to draw the remaining $7.5 million any time before November 1, 2011, subject to the achievement of certain clinical milestones and other customary conditions.

The company said it will use the funds to support clinical development activities, focusing on the phase II trials of PX-866, Oncothyreon’s irreversible inhibitor of the PI-3 kinase pathway.

Oncothyreon also said it expects the funding, in addition to existing cash and short-term investments, to financially carry the company’s operations through the second half of 2010.

“This loan facility will provide us with significant financial flexibility to carry out our planned development of both PX-866 and ONT-10, while we await the results of the START trial of Stimuvax(R),” Robert L. Kirkman, M.D., president and CEO of Oncothyreon stated in the press release.

Kirkman said the company has already commenced two of four planned phase I/II and phase II trials of PX-866 and that the company remains on track to file an Investigational New Drug application with the FDA for ONT-10 in the second half of 2011.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.